Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

129
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
129
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

143
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
143
Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

12.9K
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
12.9K
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

631
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
631
Evolutionary Relationships through Genome Comparisons02:54

Evolutionary Relationships through Genome Comparisons

5.9K
Genome comparison is one of the excellent ways to interpret the evolutionary relationships between organisms. The basic principle of genome comparison is that if two species share a common feature, it is likely encoded by the DNA sequence conserved between both species. The advent of genome sequencing technologies in the late 20th century enabled scientists to understand the concept of conservation of domains between species and helped them to deduce evolutionary relationships across diverse...
5.9K
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

160
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
160

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Imagining Genomics and Population Health in 2050: Anticipating Future Research, Policy, and Governance Needs.

Public health genomics·2026
Same author

Paths of legal recognition of genetic counselors in Canada: A framework for action.

Journal of genetic counseling·2026
Same author

Prenatal therapies: a Points to Consider framework for responsible innovation.

BMC medical genomics·2025
Same author

Toward ethical provenance tracking: The GA4GH model data access agreement (DAA).

Genetics in medicine : official journal of the American College of Medical Genetics·2025
Same author

Revisiting Professionalism and Breach of Confidentiality: Are "Neutral" Conditions the Answer?

The American journal of bioethics : AJOB·2025
Same author

Lessons learnt from moving an intensive care unit into a new hospital.

Journal of the Intensive Care Society·2025

Related Experiment Video

Updated: May 6, 2026

Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

9.9K

Life insurance: genomic stratification and risk classification.

Yann Joly1, Hilary Burton2, Bartha Maria Knoppers1

  • 1Center of Genomics and Policy, McGill University, Montreal, QC, Canada.

European Journal of Human Genetics : EJHG
|October 17, 2013
PubMed
Summary

Advancements in genomic technologies complicate genetic discrimination discussions for life insurance. Experts recommend actions to address concerns regarding genomic data use in underwriting.

More Related Videos

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease
09:34

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease

Published on: April 4, 2018

36.1K
Screening for Functional Non-coding Genetic Variants Using Electrophoretic Mobility Shift Assay EMSA and DNA-affinity Precipitation Assay DAPA
11:35

Screening for Functional Non-coding Genetic Variants Using Electrophoretic Mobility Shift Assay EMSA and DNA-affinity Precipitation Assay DAPA

Published on: August 21, 2016

12.5K

Related Experiment Videos

Last Updated: May 6, 2026

Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

9.9K
Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease
09:34

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease

Published on: April 4, 2018

36.1K
Screening for Functional Non-coding Genetic Variants Using Electrophoretic Mobility Shift Assay EMSA and DNA-affinity Precipitation Assay DAPA
11:35

Screening for Functional Non-coding Genetic Variants Using Electrophoretic Mobility Shift Assay EMSA and DNA-affinity Precipitation Assay DAPA

Published on: August 21, 2016

12.5K

Area of Science:

  • Genomics and Bioinformatics
  • Insurance Law and Ethics
  • Genetic Risk Prediction

Background:

  • The increasing accessibility of genomic tools like next-generation sequencing and genome-wide association studies has intensified the debate on genetic discrimination in life insurance.
  • A multidisciplinary group of international experts convened to review the complex legal, social, and ethical issues surrounding the use of genomic information in life insurance underwriting.

Discussion:

  • Experts addressed whether recent genomic developments alter the genetics and life insurance debate.
  • The relevance of genomic results from research contexts for life insurance underwriting was examined.
  • The applicability of genomic predictive risk assessment and stratification models in life insurance underwriting was discussed.

Key Insights:

  • Genomic advancements necessitate a re-evaluation of current practices and potential future scenarios in life insurance.
  • The ethical implications of using predictive genetic information for underwriting require careful consideration.
  • Distinguishing between research and clinical/underwriting contexts for genomic data is crucial.

Outlook:

  • The Expert Group identified key questions regarding the impact of genomics on life insurance underwriting.
  • Specific action items were recommended for stakeholders to mitigate concerns over genomic data use.
  • Further dialogue is needed to establish responsible frameworks for genomic information in the insurance sector.